Following on from the recent success of the messenger RNA (mRNA) vaccines, Nutcracker Therapeutics Inc of the US has raised $167 million in Series C financing to improve its RNA manufacturing platform and help the pharma industry develop new RNA therapeutics. The financing round was led by ARCH Venture Partners, which also has investments in Illumina Inc and Alnylam Pharmaceuticals Inc.
